Share This Author
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
A prospective natural-history study of coronary atherosclerosis.
In patients who presented with an acute coronary syndrome and underwent percutaneous coronary intervention, major adverse cardiovascular events occurring during follow-up were equally attributable to recurrence at the site of culprit lesions and to nonculprit lesions.
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Bivalirudin during primary PCI in acute myocardial infarction.
In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events.
Extrapulmonary manifestations of COVID-19
The extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 are reviewed to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved.
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluted stents than with bare-metal stents, and both drug-elution stents were associated with a marked reduction in target-lesion revascularization.
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up